Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00863512 · ClinicalTrials.gov registry record · Phase 3
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Terminated
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT00863512 is a Phase 3 study that was terminated before completion, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 34 participants.
The verdict
NCT00863512, a Phase 3 study, was terminated before completion, sponsored by Alliance for Clinical Trials in Oncology.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, cisplatin, docetaxel, gemcitabine, and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sometimes after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether chemotherapy is more effective than observation in treating patients who have undergone surgery for stage I non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying four chemotherapy regimens to see how well they work compared with observation in treating patients with early stage non-small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG docetaxel
- DRUG gemcitabine hydrochloride
- DRUG pemetrexed disodium
- DRUG vinorelbine tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00863512
The ClinicalTrials.gov registry entry for NCT00863512 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00863512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00863512 about?
NCT00863512 is a clinical study titled "Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as vinorelbine, cisplatin, docetaxel, gemcitabine, and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sometimes after surgery, the tumor may not need more treatm...
What is the current status of trial NCT00863512?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2009-03. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00863512?
The interventions under investigation include: cisplatin (DRUG), docetaxel (DRUG), gemcitabine hydrochloride (DRUG), pemetrexed disodium (DRUG), vinorelbine tartrate (DRUG).
Who is sponsoring clinical trial NCT00863512?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.